GGrantIndex
Sort

48,018 grants matching immunotherapy

Immunotherapeutic targeting of gangliosides in Ewing Sarcoma

$755,393
Robbie G. Majzner · Dana-Farber Cancer Inst · U01 · FY2024 · CA

Cyclic Flow Cytometry for Ultra-High Marker Single-Cell Analysis

$755,367
Sheldon J.j. Kwok · Lase Innovation Inc. · R44 · FY2022 · GM

Human Immune Responses to Tumor Antigens for Cancer Vaccine Development

$755,122
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Phosphorylatable Monoclonal Antibodies for Tumor Therapy

$755,009
Pbl Biomedical Laboratories · R44 · FY2002 · CA

Characterizing the therapeutic efficacy of CD8 T cell responses induced by the IL-15 superagonist ALT-803

$754,981
Shelby L Oconnor · University Of Wisconsin-Madison · R01 · FY2023 · AI

Development of Recombinant Toxins to Treat Hematologic Malignancies

$754,944
Robert Kreitman · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Mechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell Carcinoma

$754,861
Nicole Schmitt · National Institute On Deafness And Other Communication Disorders · ZIA · FY2016 · DC

Hydrogel microparticle technology for high-throughout screening of chimeric antigen receptor-T cells based on single cell effector function

$754,792
Joseph De Rutte · Partillion Bioscience Corporation · R44 · FY2023 · GM

New therapeutics for Shiga toxin-E. coli disease.

$754,653
Tom G Obrig · University Of Maryland Baltimore · U01 · FY2008 · AI

Mechanisms and Therapeutic Targeting of T cell Regulation in Heart Allograft Recipient Monkeys

$754,653
Mohamed B Ezzelarab · University Of Pittsburgh At Pittsburgh · U01 · FY2024 · AI

Temporal Transcriptomics in Hospitalized COVID-19 Patients from Disparately Impacted Ancestral Groups for Therapeutic Discovery

$754,597
Douglas Jay Perkins · University Of New Mexico Health Scis Ctr · R01 · FY2022 · AI

Discovery of novel tau proteoforms as biomarker candidates for AD and PSP

$754,586
Jeffrey Dage · Indiana University Indianapolis · R01 · FY2025 · AG

Development of therapeutic chemokine-based formulations

$754,563
Arya Biragyn · National Institute On Aging · ZIA · FY2014 · AG

Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors

$754,519
Christopher C. Derenzo · St. Jude Children'S Research Hospital · R01 · FY2025 · CA

Discovery of host genetic elements affecting response to immune checkpoint inhibitors

$754,511
Edison Tak-Bun Liu · Jackson Laboratory · R01 · FY2025 · CA

Vascular macrophages and T cells in atherosclerosis

$754,375
Klaus F. Ley · Augusta University · R35 · FY2024 · HL

BALTIMORE PEDIATRIC AIDS CLINICAL TRIALS GROUP

$754,374
Johns Hopkins University · U01 · FY2000 · AI

Modulation of B Cell Responses in Autoimmunity

$754,006
Duke University · U19 · FY2004 · AI

Molecular Allergy

$753,852
Geoffrey Mueller · National Institute Of Environmental Health Sciences · ZIA · FY2023 · ES

Characterizing the therapeutic efficacy of CD8 T cell responses induced by the IL-15 superagonist ALT-803

$753,619
Shelby L Oconnor · University Of Wisconsin-Madison · R01 · FY2021 · AI

Targeting Neuroblastoma with armed T cells

$753,575
Lawrence G Lum · Wayne State University · R01 · FY2015 · CA

Identification and eliminationof HIV reservoirs in oral lymphoid tissues by engineered NK cells.

$753,568
Jonathan Karn · Case Western Reserve University · R01 · FY2018 · DE

Activated NK CAR Cells to Cure HIV

$753,478
Pamela J Skinner · University Of Minnesota · R01 · FY2023 · AI

Activated NK CAR Cells to Cure HIV

$753,478
Pamela J Skinner · University Of Minnesota · R01 · FY2022 · AI

Activated NK CAR Cells to Cure HIV

$753,478
Pamela J Skinner · University Of Minnesota · R01 · FY2024 · AI